All In Biotech

Drug Trial Radar · NCT02814097

A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

Last checked: Nov 20, 2026Latest source record: Sep 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Sep 2, 2016

Primary completion

May 4, 2017

Study completion Jun 2, 2017

Sponsor

Lead sponsor
Stealth BioTherapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Charite University, Berlin, Germany; SCIRENT Clinical Research and Science d.o.o.
First posted
Jun 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131 (elampretide) on left ventricular function.

Conditions

  • Chronic Heart Failure

Interventions

  • elamipretideDrug

    Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days

  • PlaceboDrug

    Subcutaneous injection of placebo administered once daily for 28 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the delta in E/e' at rest exercise measured with echocardiography between the elamipretide and placebo groupsTime frame: 4 weeks

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum

    Berlin, Germany

  • German Heart Center

    Berlin, Germany

  • Clinical Centre of Serbia, Clinic for Cardiology

    Belgrade, Serbia

  • Clinical Hospital Center "Dr Dragiša Mišović-Dedinje", Department of Cardiology

    Belgrade, Serbia

  • Clinical Hospital Center "Zvezdara", Department of Cardiology

    Belgrade, Serbia

  • Clinical Hospital Center "Bežanijska Kosa", Department of Cardiology

    Belgrade, Serbia

  • Clinical Hospital Center "Zemun", Department of Cardiology

    Belgrade, Serbia

  • Institute for Cardiovascular Diseases Vojvodina, Clinic for Cardiology

    Kamenitz, Serbia

  • Clinical Center Niš, Clinic for Cardiology

    Niš, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.